Baxter International Inc. said Thursday that it will pull back some promotional literature for its new blood-clotting drug after a warning from the U.S. Food and Drug Administration. The ...

A post-hoc analysis has identified an interrelation between peak levels of factor VIII (:FVIII) in a patient’s body in the first few hours after infusion and the efficiency of prophylaxis treatment in ...

The hemophilia A treatment Advate is the cornerstone to the future of Baxalta ($BXLT), the company that was created when Baxter International ($BAX) spun off its drug ...

A meta-analysis of post-authorization safety studies (:PASS) of the Advate demonstrated that the product lowers inhibitor rate and is safe and effective for use in routine clinical practices. The ...

ADVATE (antihemophilic factor [recombinant] plasma/albumin-free method) 4000IU for IV use by Baxter Baxter announced that the FDA has approved a new 4000 IU dosage strength of Advate (Antihemophilic ...

Deerfield, Ill., July 25, 2003 -- Baxter Healthcare Corporation announced today that the U.S. Food and Drug Administration (FDA) has approved ADVATE (Antihemophilic Factor (Recombinant), ...

DEERFIELD, Ill.--(BUSINESS WIRE)--Baxter International Inc. (NYSE:BAX) today announced the approval of ADVATE [Recombinant Human Coagulation Factor VIII for injection] for the control and prophylaxis ...

Shire plc recently launched ADVATE (Octocog alfa – Recombinant Coagulation Factor VIII) in India for the treatment and prophylaxis of bleeding in patients with haemophilia A ADVATE, which came to ...

(RTTNews) - Takeda Pharmaceutical Co. Ltd. (TAK, TKPYY.PK) announced Monday a scientific update from the AHEAD real-world study investigating the long-term outcomes associated with ADVATE ...

DUBLIN--(BUSINESS WIRE)--Research and Markets (http://www.researchandmarkets.com/research/fxqkw3/advate) has announced the addition of the "Advate (Hemophilia A and B ...

Baxter International Inc. today announced that the U.S. Food and Drug Administration (FDA) has approved ADVATE [Antihemophilic Factor (Recombinant) Plasma/Albumin Free Method] for routine prophylaxis ...

Baxter International ( BAX) presented encouraging data from the Advate [Antihemophilic Factor (Recombinant), Plasma/Albumin-Free Method] prophylaxis study at the International Society on Thrombosis ...